دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention
Hiremath, Pranoti G. MD; Aversano, Thomas MD; Spertus, John A. MD, MPH; Lemmon, Cynthia C. RN, BSN, MS; Naiman, Daniel Q. PhD; Czarny, Matthew J. MD
doi : 10.1161/CIRCINTERVENTIONS.121.011308
Volume 15(2), February 2022, p e011308
Greater insight into sex-based differences in health status can lay the foundation for more equitable health care. This study compares differences in health status of women and men in the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non-Primary Percutaneous Coronary Intervention) undergoing nonprimary percutaneous coronary intervention.
Understudied, Under-Recognized, Underdiagnosed, and Undertreated: Sex-Based Disparities in Cardiovascular Medicine
Burgess, Sonya N. PhD, MBChB
doi : 10.1161/CIRCINTERVENTIONS.121.011714
Volume 15(2), February 2022, p e011714
Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction
Henry, Timothy D. MD; Bairey Merz, C. Noel MD; Wei, Janet MD; Corban, Michel T. MD; Quesada, Odayme MD; Joung, Sandy MHDS; Kotynski, Christine L. BS; Wang, Jian ScM, MD; Lewis, Michelle BS; Schumacher, Ann M. RN, MSN, CCRA; Bartel, Ronnda L. PhD; Takagi, Hiroshi DVM; Shah, Vishal MS; Lee, Anna PhD; Sietsema, William K. PhD; Losordo, Douglas W. MD; Lerman, Amir MD
doi : 10.1161/CIRCINTERVENTIONS.121.010802
Volume 15(2), February 2022, p e010802
Coronary microvascular dysfunction results in angina and adverse outcomes in patients with evidence of ischemia and nonobstructive coronary artery disease; however, no specific therapy exists. CD34+ cell therapy increases microvasculature in preclinical models and improves symptoms, exercise tolerance, and mortality in refractory angina patients with obstructive coronary artery disease. The objective of this research was to evaluate the safety, tolerability, and efficacy of intracoronary CD34+ cell therapy in patients with coronary microvascular dysfunction.
Five-Year Outcomes After Fractional Flow Reserve-Based Deferral of Revascularization in Chronic Coronary Syndrome: Final Results From the J-CONFIRM Registry
Kuramitsu, Shoichi MD, PhD; Matsuo, Hitoshi MD, PhD; Shinozaki, Tomohiro PhD, MPH; Horie, Kazunori MD; Takashima, Hiroaki MD, PhD; Terai, Hidenobu MD; Kikuta, Yuetsu MD; Ishihara, Takayuki MD; Saigusa, Tatsuya MD, PhD; Sakamoto, Tomohiro MD, PhD; Suematsu, Nobuhiro MD, PhD; Shiono, Yasutsugu MD, PhD; Asano, Taku MD, PhD; Tsujita, Kenichi MD, PhD; Masamura, Katsuhiko MD, PhD; Doijiri, Tatsuki MD; Toyota, Fumitoshi MD; Ogita, Manabu MD, PhD; Kurita, Tairo MD, PhD; Matsuo, Akiko MD; Harada, Ken MD, PhD; Yaginuma, Kenji MD, PhD; Sonoda, Shinjo MD, PhD; Yokoi, Hiroyoshi MD; Tanaka, Nobuhiro MD, PhD; on behalf of the J-CONFIRM Investigators
doi : 10.1161/CIRCINTERVENTIONS.121.011387
Volume 15(2), February 2022, p e011387
Little large-scale data is available about the long-term (beyond 3 years) clinical outcomes after fractional flow reserve (FFR)-based deferral of revascularization in clinical practice. We sought to assess the 5-year outcomes after deferral of revascularization based on FFR.
Fractional Flow Reserve-Dichotomous Decisions in Myocardial Ischemia
Frobert, Ole MD, PhD; Gotberg, Matthias MD, PhD
doi : 10.1161/CIRCINTERVENTIONS.122.011787
Volume 15(2), February 2022, p e011787
Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease
Lin, Shen MD*,,; Guan, Changdong MSc*,,; Wu, Fan MSc; Xie, Lihua MSc; Zou, Tongqiang MSc; Shi, Yanpu MD; Chen, Sipeng MS; He, Li MD; Xu, Bo MBBS; Zheng, Zhe MD, PhD
doi : 10.1161/CIRCINTERVENTIONS.121.011312
Volume 15(2), February 2022, p e011312
Percutaneous coronary intervention (PCI) has been used increasingly as an alternative means of revascularization for patients with chronic total occlusion and multivessel disease. We investigated 5-year clinical outcomes following coronary artery bypass grafting (CABG) and PCI in patients with chronic total occlusion and multivessel disease.
Chronic Total Occlusions With Multivessel Disease; Does Bypass Grafting Beat Percutaneous Coronary Intervention?
Zaman, Sarah MBBS, PhD; Berry, Colin BSc, MBChB, PhD
doi : 10.1161/CIRCINTERVENTIONS.122.011786
Volume 15(2), February 2022, p e011786
Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial)
Khan, Kamran Ahmed FCPS(Card); Qamar, Nadeem MD; Saghir, Tahir FCPS(Card); Sial, Jawaid Akbar FCPS(Card); Kumar, Dileep FCPS(Card); Kumar, Rajesh FCPS(Card); Qayyum, Danish FCPS(Card); Yasin, Umamah FCPS(Card); Jalbani, Javed FCPS(Card); Karim, Musa MSc
doi : 10.1161/CIRCINTERVENTIONS.121.011408
Volume 15(2), February 2022, p e011408
Intracoronary epinephrine has been effectively used in treating refractory no-reflow, but there is a dearth of data on its use as a first-line drug in normotensive patients in comparison to the widely used adenosine.
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2
Mangner, Norman MD; Farah, Ahmed MD; Ohlow, Marc-Alexander MD; Mobius-Winkler, Sven MD; Weilenmann, Daniel MD; Wohrle, Jochen MD; Linke, Axel MD; Stachel, Georg MD; Markovic, Sinisa MD; Leibundgut, Gregor MD; Rickenbacher, Peter MD; Cattaneo, Marco PhD; Gilgen, Nicole MD; Kaiser, Christoph MD; Scheller, Bruno MD; Jeger, Raban V. MD; for the BASKET-SMALL 2 Investigators
doi : 10.1161/CIRCINTERVENTIONS.121.011325
Volume 15(2), February 2022, p e011325
Drug-coated balloons (DCBs) are an established treatment strategy for coronary artery disease. Randomized data on the application of DCBs in patients with an acute coronary syndrome (ACS) are limited. We evaluated the impact of clinical presentation (ACS versus chronic coronary syndrome) on clinical outcomes in patients undergoing DCB or drug-eluting stent (DES) treatment in a prespecified analysis of the BASKET-SMALL 2 trial (Basel Kosten Effektivitats Trial-Drug-Coated Balloons Versus Drug-Eluting Stents in Small Vessel Interventions).
Correlation and Relative Prognostic Value of Fractional Flow Reserve and Pd/Pa of Nonculprit Lesions in ST-Segment-Elevation Myocardial Infarction
Piroth, Zsolt MD, PhD*,; Fulop, Gabor MD*,; Boxma-de Klerk, Bianca M. PhD; Abdelghani, Mohammad MD, PhD; Omerovic, Elmir MD; Andreka, Peter MD, PhD; Fontos, Geza MD; Neumann, Franz-Josef MD; Richardt, Gert MD, PhD; Smits, Pieter C. MD, PhD
doi : 10.1161/CIRCINTERVENTIONS.121.010796
Volume 15(2), February 2022, p e010796
The applicability of resting indices to guide noninfarct-related artery revascularization in ST-elevation myocardial infarction is unknown.
Pivotal Study Evaluating the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction
Murphy, Erin MD; Gibson, Kathleen MD; Sapoval, Marc MD, PhD; Dexter, David J. MD; Kolluri, Raghu MS, MD, RVT; Razavi, Mahmood MD; Black, Stephen MD
doi : 10.1161/CIRCINTERVENTIONS.121.010960
Volume 15(2), February 2022, p e010960
Iliofemoral venous obstruction is recognized with increasing frequency as the underlying cause of lower extremity symptoms including edema, pain, skin changes, and, in advanced cases, ulceration. This study sought to evaluate the safety and effectiveness of the Abre venous self-expanding stent system for the treatment of symptomatic iliofemoral venous outflow obstruction.
Coronary Access After Transcatheter Aortic Valve Replacement With Commissural Alignment: The ALIGN-ACCESS Study
Tarantini, Giuseppe MD, PhD*; Nai Fovino, Luca MD, PhD*; Scotti, Andrea MD; Massussi, Mauro MD; Cardaioli, Francesco MD; Rodino, Giulio MD; Benedetti, Alice MD; Boiago, Mauro MD; Matsuda, Yuji MD, PhD; Continisio, Saverio MD; Montonati, Carolina MD; Cacciavillani, Luisa MD, PhD; Pavei, Andrea MD, PhD; Masiero, Giulia MD; Napodano, Massimo MD, PhD; Fraccaro, Chiara MD, PhD; Fabris, Tommaso MD; Iliceto, Sabino MD, PhD
doi : 10.1161/CIRCINTERVENTIONS.121.011045
Volume 15(2), February 2022, p e011045
Coronary access (CA) after transcatheter aortic valve replacement (TAVR) with supra-annular transcatheter heart valves (THV) can be challenging. Specific Evolut R/Pro and Acurate Neo THVs orientations are associated with reduced neo-commissure overlap with coronary ostia, while SAPIEN 3 THV cannot be oriented. With the ALIGN-ACCESS study (TAVR With Commissural Alignment Followed by Coronary Access), we investigated the impact of commissural alignment on the feasibility of CA after TAVR.
Economic Considerations in Access to Transcatheter Aortic Valve Replacement
Reddy, Kriyana P. BS; Groeneveld, Peter W. MD, MS; Giri, Jay MD, MPH; Fanaroff, Alexander C. MD, MHS; Nathan, Ashwin S. MD, MS
doi : 10.1161/CIRCINTERVENTIONS.121.011489
Volume 15(2), February 2022, p e011489
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, with the number of procedures and sites offering the procedure steadily rising over the past decade in the United States. Despite this, growth into certain markets has been limited as hospitals have to balance high TAVR costs with the ability to offer a complete array of state-of-the-art therapies for aortic stenosis. This trade-off often results in decreased access to TAVR services by patients cared for in hospitals that cannot afford these services or have difficulty meeting procedural requirements, recruiting skilled physicians, and initiating and then maintaining a functioning TAVR program. The lack of access is more common among patients of color or those who are socioeconomically disadvantaged. The purpose of this review is to describe the hospital-level economic considerations of TAVR in the United States and the resulting effects on geographic, racial, ethnic, and socioeconomic access for Americans.
